fluoxetine has been researched along with Machado-Joseph Disease in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Machado-Joseph Disease: A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death." | 6.71 | Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. ( Ferro, A; Jardim, LB; Monte, TL; Pereira, ML; Rieder, CR; Rockenback, I; Sequeiros, J; Silveira, I; Tort, AB, 2003) |
| "Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death." | 2.71 | Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. ( Ferro, A; Jardim, LB; Monte, TL; Pereira, ML; Rieder, CR; Rockenback, I; Sequeiros, J; Silveira, I; Tort, AB, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monte, TL | 1 |
| Rieder, CR | 1 |
| Tort, AB | 1 |
| Rockenback, I | 1 |
| Pereira, ML | 1 |
| Silveira, I | 1 |
| Ferro, A | 1 |
| Sequeiros, J | 1 |
| Jardim, LB | 1 |
1 trial available for fluoxetine and Machado-Joseph Disease
| Article | Year |
|---|---|
Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study.
Topics: Adolescent; Adult; Cognition; Depression; Female; Fluoxetine; Humans; Machado-Joseph Disease; Male; | 2003 |